What compounds target CDK6?

BiohacksAI has identified 31 compounds that interact with CDK6 (cyclin dependent kinase 6). Top compounds include: seliciclib, alvocidib, palbociclib, dinaciclib, abemaciclib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is CDK6 (cyclin dependent kinase)?

CDK6 is cyclin dependent kinase 6. It is a molecular target for 31 compounds documented in PubMed bioassay data. UniProt ID: Q00534. NCBI Gene ID: 1021.

CDK6

MOLECULAR TARGET

cyclin dependent kinase 6

UniProt: Q00534 NCBI Gene: 102131 compounds

CDK6 (cyclin dependent kinase 6) is targeted by 31 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CDK6

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	seliciclib	4.91	135
2	alvocidib	4.52	91
3	palbociclib	4.22	67
4	dinaciclib	3.87	47
5	abemaciclib	3.66	38
6	bms 387032	3.47	31
7	at 7519	3.33	27
8	dabrafenib	3.30	26
9	ribociclib	3.26	25
10	sulfuretin	3.14	22
11	dovitinib	3.09	21
12	at 9283	3.09	21
13	lestaurtinib	3.04	20
14	momelotinib	2.89	17
15	k 252a	2.83	16
16	milciclib	2.77	15
17	azd 5438	2.71	14
18	fascaplysin chloride	2.64	13
19	zotiraciclib	2.56	12
20	ct 7001	2.20	8
21	cyc 116	2.08	7
22	rg 547	2.08	7
23	zemirciclib	2.08	7
24	ebvaciclib	2.08	7
25	pf 03814735	1.79	5
26	voruciclib	1.79	5
27	Apigenin 5,7,4'-trihydroxy-flavone,	1.39	3
28	chrysin	1.39	3
29	fisetin	1.39	3
30	indirubin	0.69	1
31	Sorafenib	0.69	1

About CDK6 as a Drug Target

CDK6 (cyclin dependent kinase 6) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 31 compounds with documented CDK6 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CDK6 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.